Year: 2025

New York, NY, Dec. 31, 2025 (GLOBE NEWSWIRE) — Westin Acquisition Corp (NASDAQ): WSTNU, the “Company”), a Cayman Islands exempted company, announced that holders of its 5,750,000 units sold in the Company’s initial public offering may elect to separately trade the ordinary shares and rights included in the units, commencing on or about December 31, 2025. This press release supersedes the Company’s press release dated December 23, 2025. Any units not separated will continue to trade on the Nasdaq Capital Market (the “Nasdaq”) under the symbol “WSTNU,” and the separated ordinary shares and rights are expected to trade on the Nasdaq under the symbols “WSTN” and “WSTNR”, respectively. Holders of units will need to have their brokers contact Odyssey Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate...

ROBESONIA, Pa., Dec. 31, 2025 (GLOBE NEWSWIRE) — BLAQclouds, Inc. (OTC: BCDS), a Web3 infrastructure, fintech, and digital asset company, today announced the planned spinout of BLAQclouds Property Group, a wholly owned subsidiary formed in Wyoming that is focused on the acquisition and management of income-producing, brick-and-mortar commercial real estate. CLICK HERE for corporate details. The Company has set an ex-dividend date of January 5, 2026, at 4:00 PM Eastern Time, for the distribution of shares in BLAQclouds Property Group to eligible BLAQclouds shareholders.Spinout Distribution DetailsBLAQclouds Property Group, Inc. a Wyoming Corporation (formation date 12/11/24) https://www.bpginc.io/ 100,000,000 common shares authorized, no par, no preferred Distribution Ratio:Shareholders will receive one (1) share of BLAQclouds...

TARPON SPRINGS, Fla., December 31, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today issued the following letter to shareholders from the Company’s Chief Executive Officer. Dear Shareholders, As we close out 2025, I write to you with both optimism and gratitude. Your continued support has helped steer Allarity Therapeutics through a period of meaningful transformation and disciplined execution. This December marks two years since I assumed the role of Chief Executive Officer. Since that time, our efforts have been anchored by a clear and focused strategy centered on advancing stenoparib, our novel dual inhibitor of PARP and the WNT pathway- for advanced ovarian...

HOUSTON, Dec. 31, 2025 (GLOBE NEWSWIRE) — HyOrc Corporation (OTCID: HYOR), a clean-energy technology company, today announced the successful completion of the Factory Acceptance Test (FAT) for its 500kW Organic Rankine Cycle (ORC) turbine, which is now being prepared for shipment to Camsan Ordu, a customer project in Turkey. The FAT was witnessed and independently inspected by Bureau Veritas, a global testing, inspection, and certification group. The inspection was carried out on 30 December 2025 at the HyOrc / EnerTek manufacturing facility in Tamil Nadu, India. According to the Bureau Veritas inspection report, the HyOrc 500kW ORC turbine successfully completed witnessed speed and RPM testing across multiple nozzle configurations, demonstrating smooth acceleration, stable RPM, and no abnormal vibration, noise, or mechanical instability. No...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Dec. 31, 2025 (GLOBE NEWSWIRE) — Reeflex Solutions Inc. (TSXV: RFX) (“Reeflex” or the “Company”) announces that, further to its announcement on December 17, 2025, the Alberta Securities Commission (the “ASC”), as principal regulator of the Company, has issued a management cease trade order (“MCTO”) under National Policy 12-203 Management Cease Trade Orders (“NP 12-203”). The Company applied for the MCTO in connection with the inability to file its audited annual financial statements, management’s discussion and analysis and related CEO and CFO certifications for the financial year ended August 31, 2025 (collectively, the “Annual Filings”) by the required deadline of December 29, 2025 (the “Filing Deadline”) under Part 4 of...

MedSell commercializes Lumee™ Oxygen tissue monitoring in France, building upon distributor partnerships in Spain, Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia, to now reach approximately 200,000 annual CLI cases in the European Union Agreement complements KOL collaboration with Vascular Center at Groupe Hospitalier Paris Saint Joseph, Paris that accounts for approximately 8% of all CLTI cases in France BERKELEY, Calif, Dec. 31, 2025 (GLOBE NEWSWIRE) — Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, announces a new distributor partnership in France with MedSell.  MedSell is a French company that specializes in the commercialization...

Tel Aviv, Israel, Dec. 31, 2025 (GLOBE NEWSWIRE) — Jeffs’ Brands Ltd (“Jeffs’ Brands” or the “Company”) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company strategically pivoting into homeland security, today announced that the board of directors of its majority-owned subsidiary, Fort Technology Inc. (TSXV: FORT) (“Fort”), approved a strategic initiative to pursue an uplisting of Fort’s common shares on the Nasdaq Capital Market (“Nasdaq”). Fort believes that a listing on Nasdaq will provide enhanced visibility, greater liquidity for its shareholders, and access to a broader pool of institutional and retail investors in the United States and internationally. Fort’s management intends to commence the necessary preparations, including engaging advisors, preparing required filings with the U.S. Securities and Exchange Commission...

Luotea PlcStock exchange release31 December 2025 at 2.10 pm The partial demerger of Lassila & Tikanoja plc has been registered – New Lassila & Tikanoja to be listed on Nasdaq Helsinki The completion of the partial demerger (the “Demerger”) of Lassila & Tikanoja plc (“Lassila & Tikanoja” or the “Demerging Company”) has today on 31 December 2025 been registered with the Finnish Trade Register. Lassila & Tikanoja announced on 7 August 2025 the approval of the demerger plan concerning the Demerger (the “Demerger Plan”) according to which all assets, debts and liabilities of Lassila & Tikanoja relating to the circular economy business area or mainly serving the circular economy business area of Lassila & Tikanoja are transferred without a liquidation procedure to the new Lassila & Tikanoja Plc (the “New...

New Drug Application (NDA) submission on track for January 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has received formal pre-New Drug Application (NDA) meeting minutes from the U.S. Food and Drug Administration (FDA) supporting an NDA submission for AXS-12 in narcolepsy. AXS-12 (reboxetine) is a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator. The purpose of the meeting was to reach agreement with the FDA on the proposed content and format of the Company’s planned NDA submission including the clinical and nonclinical requirements. Based on the feedback from the FDA, the Company’s regulatory data package would...